文献速递神经肿瘤

重新审视胶质瘤的软脑膜转移:基于增强后液体衰减反转恢复成像的发病率与分子预测因素

Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging.
PubMed 文献 · J Neurosurg · 2022-11-04

研究纳入2001至2021年1405例成人胶质瘤(WHO 2-4级)患者,在初诊及治疗监测中行增强后FLAIR成像。软脑膜转移(LM)见于228例(16.2%),初诊时110例(7.8%),复发时118例(8.4%)。IDH野生型(OR 3.14,p=0.001)和MGMT启动子未甲基化(OR 1.43,p=0.034)是LM的独立预测因素。

要点

  • 增强后FLAIR成像显示成人胶质瘤LM总体发生率为16.2%。
  • IDH野生型(OR 3.14)和MGMT启动子未甲基化(OR 1.43)为LM独立预测因素。
  • LM患者中位OS较无LM患者更差(16.7 vs 32.0个月,p<0.001)。

核心结论

  • 脑脊液敏感成像有助于LM诊断,显示成人胶质瘤中LM发生率较高。
  • 分子标志物与胶质瘤LM发生相关,具有侵袭性分子标志物的患者需进行LM影像学监测。

研究设计与样本

  • 研究纳入2001至2021年间1405例成人胶质瘤(WHO 2-4级)患者,在初诊及治疗监测中行增强后FLAIR成像。
  • 收集的分子数据包括IDH突变、1p/19q共缺失、H3 K27改变和MGMT启动子甲基化状态。
  • 采用包含增强后FLAIR序列的MRI进行LM诊断,并对LM发生进行逻辑回归分析。
  • 比较有无LM患者的总生存期(OS)。

主要发现

  • 228例(16.2%)患者发现LM,其中初诊时110例(7.8%),复发时118例(8.4%)。
  • IDH野生型(OR 3.14,p=0.001)和MGMT启动子未甲基化(OR 1.43,p=0.034)是LM的独立预测因素。
  • 初诊时LM与WHO 4级(OR 10.52,p<0.001)和非脑叶位置(OR 1.56,p=0.048)相关。
  • 复发时LM与IDH野生型(OR 5.04,p<0.001)和H3 K27改变(OR 3.39,p=0.003)相关。
  • LM患者中位OS较无LM患者更差(16.7 vs 32.0个月,p<0.001,log-rank检验),多因素Cox分析证实其为独立因素(p=0.004)。

临床怎么用

  • 作者认为,脑脊液敏感成像有助于LM诊断。
  • 作者认为,具有侵袭性分子标志物的患者需进行LM影像学监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Leptomeningeal metastases (LMs) in glioma have been underestimated given their low incidence and the lack of reliable imaging. Authors of this study aimed to investigate the real-world incidence of LMs using cerebrospinal fluid (CSF)-sensitive imaging, namely postcontrast fluid-attenuated inversion recovery (FLAIR) imaging, and to analyze molecular predictors for LMs in the molecular era. METHODS: A total of 1405 adult glioma (World Health Organization [WHO] grade 2-4) patients underwent postcontrast FLAIR imaging at initial diagnosis and during treatment monitoring between 2001 and 2021. Collected molecular data included isocitrate dehydrogenase (IDH) mutation, 1p/19q codeletion, H3 K27 alteration, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status. LM diagnosis was performed with MRI including postcontrast FLAIR sequences. Logistic regression analysis for LM development was performed with molecular, clinical, and imaging data. Overall survival (OS) was compared between patients with and those without LM. RESULTS: LM was identified in 228 patients (16.2%), 110 (7.8%) at the initial diagnosis and 118 (8.4%) at recurrence. Among the molecular diagnostics, IDH-wildtype (OR 3.14, p = 0.001) and MGMT promoter unmethylation (OR 1.43, p = 0.034) were independent predictors of LM. WHO grade 4 (OR 10.52, p < 0.001) and nonlobar location (OR 1.56, p = 0.048) were associated with LM at initial diagnosis, whereas IDH-wildtype (OR 5.04, p < 0.001) and H3 K27 alteration (OR 3.39, p = 0.003) were associated with LM at recurrence. Patients with LM had a worse median OS than those without LM (16.7 vs 32.0 months, p < 0.001, log-rank test), which was confirmed as an independent factor on multivariable Cox analysis (p = 0.004). CONCLUSIONS: CSF-sensitive imaging aids the diagnosis of LM, demonstrating a high incidence of LM in adult gliomas. Furthermore, molecular markers are associated with LM development in glioma, and patients with aggressive molecular markers warrant imaging surveillance for LM.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Park YW, Han K, Park JE, et al. Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging. J Neurosurg. 2022. PMID: 36334295. doi:10.3171/2022.9.JNS221659

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。